F0806
Factor IX human
aqueous glycerol solution, ≥145 units/mg protein
Synonym(e):
Christmas factor, Plasma thromboplastin component
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Über diesen Artikel
Form:
aqueous glycerol solution
Biological source:
human
Mol wt:
55 kDa
Fortfahren mit
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten1 of 4
Dieser Artikel | |||
|---|---|---|---|
| technique(s) ligand binding assay: suitable | technique(s) - | technique(s) - | technique(s) ligand binding assay: suitable |
| biological source human | biological source - | biological source - | biological source human |
| mol wt 55 kDa | mol wt - | mol wt - | mol wt - |
| form aqueous glycerol solution | form liquid | form liquid | form aqueous glycerol solution |
| shipped in wet ice | shipped in wet ice | shipped in wet ice | shipped in wet ice |
| specific activity ≥145 units/mg protein | specific activity ≥20 units/mg protein | specific activity ≥85 units/mg protein (clotting assay) | specific activity ≥25 units/mg protein |
General description
Factor IX is a 55 kDa single chain vitamin K-dependent plasma zymogen which plays a key role in the intrinsic and extrinsic blood coagulation systems.
Application
Factor IX is plasma zymogen key to blood coagulation systems. It has been used in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC). It has been found that abnormalities in factor IX contribute to PVT in HCC patients. Additionally, it has been used in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD).
Physical form
Aqueous solution containing 50% (v/v) glycerol
Other Notes
One unit is equivalent to the Factor IX activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
View this factors role in the Coagulation Cascade
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Lagerklasse
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Uri Martinowitz et al.
Thrombosis research, 131 Suppl 2, S11-S14 (2013-03-30)
Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) is a novel recombinant albumin fusion protein designed to extend the half-life of recombinant factor IX (rFIX), which is used in the management of hemophilia B. Clinical evaluation of rIX-FP
Elena Santagostino
Thrombosis research, 131 Suppl 2, S7-10 (2013-03-30)
Hemophilia B is a severe bleeding disorder that is characterized by a deficiency or dysfunction of coagulation factor IX (FIX). Replacement therapy using recombinant or plasma-derived FIX is available, but the relatively short half-life of FIX (approximately 18 hours) necessitates
Priya Verghese et al.
Pediatric nephrology (Berlin, Germany), 28(5), 823-826 (2013-02-06)
Nephrotic syndrome (NS) is a recognized complication of immune tolerance induction (ITI) therapy, a treatment strategy used to treat inhibitors in patients with hemophilia B receiving factor IX concentrate. We present a 4-year-old boy with hemophilia B and an inhibitor
[Hemophilia].
Midori Shima
[Rinsho ketsueki] The Japanese journal of clinical hematology, 54(2), 189-197 (2013-03-09)
Mariko Yamamoto et al.
[Rinsho ketsueki] The Japanese journal of clinical hematology, 54(3), 300-304 (2013-05-17)
This report describes the successful management of neurosurgical procedures with continuous infusion of recombinant factor IX (rFIX). A 1-year-old boy with severe hemophilia B was administered prophylactic therapy with rFIX after intracranial bleeding. We found the enlargement of an arachnoid
Verwandter Inhalt
Instructions
Active Filters
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung